Tweet
The bioinformatic person is doing all that. She trimmed the adapters and tried aligning the reads to the genome using tophat. She got 40% alignment there. We tried blasting some of the unaligned reads and realized that something went wrong with the tophat run as some of them were aligning to chromosome M, chr 1, 4 etc. She will be doing the alignment again with STAR this time but to save on time she also ran the RSEM along side and got these low percentage alignments to transcriptome so I wanted to know if we are missing out on anything?
-
-
It would be helpful if you posted some basic quality metrics, such as you get from FastQC. There's not enough information to determine what the problem is or even if there is a problem.Comment
-
Ok. I have looked at the FastQC report of the samples and it looks fine to me. What kind of information should I give from FastQC report?Comment
-
The whole thing as PDF is good way to start. But particularly the quality histograms, anything that failed the tests, and anything related to mapping. And the stats from adapter trimming, the command lines you used for each program, the top hits and mapping rate you got from Blast... etc.Comment
-
I will have to ask my bioinformatician for the stats after adapter trimming. I will get back on this. Thanks for your time.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...Yesterday, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment